Biopharma: Clinical Trial Pipeline Tracker – Obesity and Oncology Accelerate, But Trial Adjustments Signal Rising Execution Risk

Core Conclusion

The biopharma pipeline is shifting aggressively into obesity (GLP-1 switches and combinations) and oncology (next-gen CAR-T, bispecifics), with multiple Phase 3 trial recruitments completed. However, the market may be misreading trial downsizing and primary completion date pull-ins as purely positive. In reality, these often reflect protocol amendments, futility analysis, or recruitment difficulties. Key data catalysts from BMS Milvexian, Lilly Donanemab, and Regeneron Odronextamab offer binary optionality, while obesity pipeline expansion suggests faster competitive erosion for incumbents.

What the Market May Be Underpricing

Three hidden risk signals are overlooked: 1) Trial size downsizing (e.g., BMS Milvexian –16.5% from 15,000 to 12,532) can indicate protocol changes or recruitment challenges, not just efficiency. 2) Primary completion date pull-ins (e.g., Biogen Omaveloxolone advanced ~4.5 years) often precede early termination for futility or safety, yet are sometimes read as positive. 3) The rapid obesity pipeline ramp (Amgen MARITIME-SWITCH, Pfizer SOLIS-1) will compress the competitive timeline faster than consensus models assume, pressuring legacy GLP-1 players.

Evidence Chain

Obesity pipeline is accelerating with GLP-1 switch and combination trials

• Amgen initiated Phase 3 MARITIME-SWITCH (n=300) evaluating Maridebart Cafraglutide directly switching from GLP-1 RA.
• Pfizer initiated Phase 2 SOLIS-1 (n=872) testing MET-097i ULA GLP-1 plus Met-233i ULA Amylin combination.
• Lilly/Regeneron completed Phase 2 tirzepatide+mibavademab (n=392) in obesity.

Investment implication: Entrants will challenge Novo Nordisk and Lilly faster than expected; watch Amgen and Pfizer for early proof-of-concept.

Oncology pipelines show new head-to-head competition and early fragility

• Gilead started KITE-753 (novel CAR-T) vs. Yescarta Phase 3 (n=550) in lymphoma.
• Merck started Phase 2/3 MK-1045 (CD19xCD3 bispecific) for B-ALL (n=340).
• Pfizer terminated three Phase 1 oncology trials (total ~104 patients) in April 2026.
• Merck terminated V940 skin cancer vaccine trial after only 46 patients.

Investment implication: Later-stage assets (KITE-753, MK-1045) offer upside optionality, but early-stage pipeline depth is thinning—multiple terminations signal weak Phase 1 success rates.

Trial size and timeline adjustments reveal hidden execution risk

• BMS Milvexian stroke trial downsized from 15,000 to 12,532 (–16.5%).
• Biogen Omaveloxolone primary completion pulled from Feb 2030 to Sep 2025 (4.5-year advance).
• Biomarin BMN 349 both delayed (Sep 2025 → Aug 2026) and downsized (12→6 patients).
• Alumis envudeucitinib downsized from 48 to 32 patients.
• BeOne Medicines BGB-58067 expanded from 244 to 525 (+115%).

Investment implication: Large pull-ins (Biogen, Sarepta) warrant skepticism; check for protocol amendments or futility analyses. Downsizing in a completed trial (Milvexian) may indicate lower statistical power.

Completed recruitment sets up binary catalysts

• BMS Milvexian stroke Phase 3 (n=12,532) completed.
• Lilly Donanemab China Phase 3 (TRAILBLAZER-ALZ 5, n=1,500) completed.
• Regeneron Odronextamab Phase 1/2 NHL completed.
• BioNTech DB-1305 Phase 1/2 (n=1,123) completed.
• Merck MK-2870 NSCLC Phase 3 completed.

Investment implication: These events are near-term binary catalysts. For Milvexian, the downsized sample reduces confidence; for Donanemab, China AD data add regulatory optionality.

Key Disagreements and Risks

• Statistical noise from tiny trials: Incyte (n=9), Biomarin (n=6) completed trials provide limited interpretability; aggregate early-phase termination trends are more informative.
• Obesity competitive intensity: Pfizer’s dual GLP-1/amylin combo faces entrenched players; proof-of-concept data needed before assigning value.
• Pull-ins may hide trouble: Biogen Omaveloxolone and Sarepta delandistrogene moxeparvovec advance by >4 years—possible early stopping for futility or safety.
• Large recruitment burden strains timelines: Pfizer VLA15 (n=1,712) and Merck colorectal cancer (n=1,020) will test execution capability.
• Early oncology pipeline churn: Pfizer three Phase 1 terminations in April 2026 and Merck V940 termination suggest industry-wide Phase 1 attrition rising.

Valuation or Trading Implications

Focus on upcoming data readouts from completed trials as binary catalysts. For BMS Milvexian, the downsized trial reduces probability of success; a bearish positioning on that asset may be warranted. For Lilly Donanemab, Chinese AD approval remains binary—positive readout would de-risk broader Alzheimer’s pipeline. For Regeneron Odronextamab, completed NHL Phase 1/2 data may support accelerated approval or confirmatory path. In obesity, monitor Amgen MARITIME-SWITCH and Pfizer SOLIS-1 for early efficacy signals; positive data would pressure incumbents.

Short-term catalysts vs. long-term pipeline health: The obesity pipeline expansion is a multi-year competitive erosion driver for Novo Nordisk and Lilly, but near-term data (Milvexian, Donanemab) offer more immediate tradeable events. Preferred exposure: long on late-stage catalysts with strong endpoint probability (e.g., Donanemab), short on assets with downsized trials (Milvexian). Monitor early-stage termination trends as a leading indicator of pipeline depth.

Appendix Data Summary (Compressed)

Exhibit 1: Key New Trials Initiated (Period: May 6–13, 2026)

Exhibit 2: Key Trials with Completed Patient Recruitment (Catalyst List)

Note: Appendix tables are compressed to show only high-value assets with largest binary impact. Full trial lists in original report.